Cernevit lyophilizate solution vial, 10pcs

Composition

Each bottle (5 ml) contains:

Active ingredients:  

Retinol (vitamin A) in the form of retinol palmitate 3500 ME,

Colecalciferol (vitamin D 3) 220 ME,

Alpha-tocopherol (vitamin E) 11.2 ME, corresponds to the amount of DL of alpha-tocopherol 10.2 mg,

Ascorbic acid (vitamin C) 125 mg,

Thiamine (vitamin B1) 3.51 mg, in the form of cocarboxylase tetrahydrate 5.8 mg,

Riboflavin (vitamin B2) 4.14 mg, in the form of riboflavin sodium phosphate dihydrate 5.67 mg,

Pyridoxine (vitamin B6) 4.53 mg, in the form of pyridoxine hydrochloride 5.50 mg,

Cyanocobalamin (vitamin B12) 6 mcg,

Folic acid (vitamin B9) 414 mcg,

Pantothenic acid (vitamin B5) 17.25 mg, in the form of dexpanthenol 16.15 mg,

Biotin (Vitamin B8) 0.069 mg,

Nicotinamide (vitamin PP) 46 mg,

Auxiliary substances:

glycine,

glycocholic acid,

soy phosphatides,

sodium hydroxide,

hydrochloric acid.

Pharmacological action

Cernevit is a balanced mixture of water-soluble and fat-soluble vitamins, which ensures a complete supply of vitamins to the body during parenteral nutrition

Indications

Supplement to parenteral nutrition for adults and children over 11 years of age.

Use during pregnancy and lactation

Use during pregnancy:

Cernevit can be prescribed during pregnancy, provided that the dosage regimen is strictly adhered to in order to avoid overdose.

You should consult your doctor or pharmacist before using any other medication. Use during lactation:

The use of Cernevit in nursing women is not recommended, since it is possible to develop an overdose of vitamin A in newborns.

Contraindications

• hypersensitivity to the components of the drug, especially vitamin B1
• children under 11 years
• of age simultaneous use of levodopa preparations

Side effects

In rare cases, some patients may have an increase in ALT (SHPT) values with intravenous bolus use.

Since the drug contains vitamin B1, it is possible to develop anaphylactic reactions in patients with delayed-type allergies.

Please contact your doctor immediately if you notice any side effects that are not listed above when using the drug.

Interaction

Due to the presence of pyridoxine (vitamin B6) in the preparation, co-use with levodopa preparations is contraindicated.

Due to the presence of folic acid in the drug, caution should be exercised when combined with antiepileptic drugs containing phenobarbital, phenytoin or primidone: clinical monitoring and, if possible, monitoring of the blood plasma content, correction of the dosage regimen of the antiepileptic drug during and after discontinuation of folic acid use is necessary.

Compatibility should be checked when preparing with other infusion solutions, especially if Cernevit is added to binary parenteral mixtures containing glucose, electrolytes, and amino acid solutions, or to mixtures containing glucose, electrolytes, amino acid solutions, and lipids.

Please tell your doctor or pharmacist what medications you have previously used, even if they were prescribed without a prescription.

How to take, course of use and dosage

The drug is intended for intravenous use only. Dosage: The recommended dose is 5-ml (1 bottle) per day

Receiving method: Using a syringe, inject 5 ml of water for injection or 5% dextrose (glucose) solution or 0.9% sodium chloride solution into the vial. Stir gently until the powder is completely dissolved (yellow-orange solution).

The resulting solution is slowly administered intravenously in a jet.

Frequency of use and duration of therapy: The use of the drug can continue for the entire period of parenteral nutrition.

Duration of appointment based on the doctor’s recommendation.

Overdose

Symptomsvitamin A overdose of more than 150,000 IU (acute): gastrointestinal disorders, headache, increased intracranial pressure, edema of the optic disc, mental disorders, excitability or even convulsions, delay in generalized epithelial desquamation.

Vitamin A overdose (chronic): increased intracranial pressure, sensitive or painful subcutaneous bulges on the fingers of the upper and lower extremities.

Treatment: stop using Cernevit, reduce the use of calcium, increase diuresis and conduct adequate rehydration of the body. No “withdrawal symptoms” were detected after discontinuation of the drug.

Special instructions

With bolus intravenous use, there were rare cases of a moderate increase in ALT (SHPT) in patients with active enterocolitis; after the end of Cernevit, elevated levels of “hepatic” transaminases quickly return to normal values. It is recommended to monitor the levels of “hepatic” transaminases in patients of this group.

Due to the presence of glycocholic acid as an auxiliary ingredient, with repeated and prolonged use of the drug in patients with jaundice or severe cholestasis (changes in the indicators of laboratory liver function tests), it is necessary to carefully monitor liver function.

Deficiency of one or more vitamins should be corrected with special medications.

Cernevit does not contain vitamin K, which can be taken separately, if necessary.

Form of production

Lyophilizate for the preparation of a solution for intravenous use

Storage conditions

In a dark place, at a temperature not exceeding 25 °C

Shelf life

3 years

Active ingredient

Multivitamins parenteral use

Conditions of release from pharmacies

By prescription

Dosage form

infusion solution